# Study Of Sunitinib In Combination With Cisplatin/Capecitabine Or Oxaliplatin/Capecitabine In Patients With Advanced Gastric Cancer

> **NCT00555620** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 76 (actual)

## Conditions studied

- Stomach Neoplasms

## Interventions

- **DRUG:** capecitabine
- **DRUG:** oxaliplatin
- **DRUG:** sunitinib malate
- **DRUG:** capecitabine
- **DRUG:** cisplatin
- **DRUG:** sunitinib malate

## Key facts

- **NCT ID:** NCT00555620
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-05
- **Primary completion:** 2010-08
- **Final completion:** 2011-12
- **Target enrollment:** 76 (ACTUAL)
- **Last updated:** 2013-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00555620

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00555620, "Study Of Sunitinib In Combination With Cisplatin/Capecitabine Or Oxaliplatin/Capecitabine In Patients With Advanced Gastric Cancer". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00555620. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*